WASHINGTON (dpa-AFX) - Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Co., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TKPYY.PK) on Thursday said they have formed a collaboration with Ventana Medical Systems, Inc., a member of the Roche Group.
Under the collaboration agreement, Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test to identify patients who might respond to treatment with ADCETRIS based on CD30 expression levels in their tissue specimens.
As part of the ongoing clinical development of ADCETRIS, Millennium and Seattle Genetics are planning two phase III studies that will use the companion diagnostic, one in CD30-positive cutaneous T-cell lymphoma and the other in CD30-positive mature T-cell lymphomas.
ADCETRIS was approved by the U.S. Food and Drug Administration in August 2011 for relapsed Hodgkin lymphoma and systemic anaplastic large call lymphoma. A molecular companion diagnostic is not required for the current FDA-approved indications for ADCETRIS.
Copyright RTT News/dpa-AFX